Q-omics provides the consensus-scored GMPR2 profile across patient tissues and cancer cell-line models. GMPR2 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, GMPR2 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, GMPR2 protein abundance shows 24,518 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight BRCA, HNSC, and PDAC as cancer lineages where GMPR2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GMPR2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GMPR2 survival associations across molecular data types. GMPR2 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (3) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GMPR2 RNA expression–survival associations across cancer types. High GMPR2 expression shows unfavorable associations in HNSC, but favorable associations in BRCA, KIRC, MESO, LGG and ACC. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for GMPR2 RNA expression.
This table summarizes GMPR2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for GMPR2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GMPR2 shows lower tumor expression in KICH, LUSC, THCA and KIRC and higher tumor expression in HNSC and LIHC. The HNSC box plot shows higher GMPR2 RNA expression in tumor versus normal tissue (log2 FC = +0.615, t-test p < 0.001).
This table shows molecular features associated with GMPR2 in patient tissues and cancer cell lines. In patient samples, GMPR2 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, GMPR2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
